Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma . mfm [Internet]. 2024 Jun. 30 [cited 2026 Oct. 12];35(6). Available from: http://medicalforummonthly.com/index.php/mfm/article/view/4698